MRKR · Insider Trading
Marker Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by MRKR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-19 | Norman David Eansor | Director | A | +221,741 deriv. | — |
| 2025-11-19 | Katharine Knobil | Director | A | +221,741 deriv. | — |
| 2025-11-19 | Steve Elms | Director | A | +221,741 deriv. | — |
| 2025-11-04 | Kathryn Penkus Corzo | Director | A | +147,611 deriv. | — |
| 2025-11-04 | Juan Vera | Chief Executive Officer | A | +250,000 deriv. | — |
| 2025-02-14 | Juan Vera | President and CEO | A | +50,000 deriv. | — |
| 2025-02-14 | Steve Elms | Director | A | +30,000 deriv. | — |
| 2025-02-14 | Norman David Eansor | Director | A | +30,000 deriv. | — |
| 2025-02-14 | Katharine Knobil | Director | A | +30,000 deriv. | — |
| 2024-12-26 | Steve Elms | Director | Buy | +11,085 | +$35.47K |
| 2024-12-23 | NEA Partners 16, L.P. | 10%+ Owner | Buy | +5,542,500 | +$17.74M |
| 2023-06-08 | Katharine Knobil | Director | A | +8,000 deriv. | — |
| 2023-06-08 | John Robert Wilson | Director | A | +8,000 deriv. | — |
| 2023-06-08 | Steve Elms | Director | A | +8,000 deriv. | — |
| 2023-06-08 | Norman David Eansor | Director | MIXED | +14,284 | +$249.99K |
| 2023-05-11 | Juan Vera | President and CEO | A | +100,000 deriv. | — |
| 2023-03-01 | Juan Vera | Chief Scientific Officer & COO | A | +46,487 deriv. | — |
| 2023-03-01 | Tsvetelina P Hoang | VP, Research and Development | A | +33,159 deriv. | — |
| 2023-03-01 | Michael Loiacono | Chief Accounting Officer | A | +38,480 deriv. | — |
| 2023-03-01 | Mythili Koneru | Chief Medical Officer | A | +51,918 deriv. | — |
| 2023-03-01 | Nadia Agopyan | SVP, Regulatory Affairs | A | +34,154 deriv. | — |
| 2023-03-01 | Anna Szymanska | Vice President, Quality | A | +29,947 deriv. | — |
| 2022-05-26 | John Robert Wilson | Director | A | +80,000 deriv. | — |
| 2022-05-26 | Steve Elms | Director | A | +80,000 deriv. | — |
| 2022-05-26 | Norman David Eansor | Director | A | +80,000 deriv. | — |
| 2022-05-26 | David Laskow-Pooley | Director | A | +80,000 deriv. | — |
| 2022-05-26 | Katharine Knobil | Director | A | +80,000 deriv. | — |
| 2022-03-28 | Juan Vera | Chief Scientific Officer & COO | MIXED | +107,358 | −$16.22K |
| 2022-03-28 | Peter L. Hoang | President and CEO | MIXED | +150,718 | −$23.45K |
| 2022-03-28 | Anthony H. Kim | Chief Financial Officer | MIXED | +114,436 | −$17.49K |
| 2022-02-22 | Peter L. Hoang | President and CEO | A | +430,000 deriv. | — |
| 2022-02-22 | Anna Szymanska | Vice President, Quality | A | +40,000 deriv. | — |
| 2022-02-22 | Anthony H. Kim | Chief Financial Officer | A | +160,000 deriv. | — |
| 2022-02-22 | Gerald Garrett | Vice President, Clinical Ops. | A | +40,000 deriv. | — |
| 2022-02-22 | Michael Loiacono | Chief Accounting Officer | A | +140,000 deriv. | — |
| 2022-02-22 | Tsvetelina P Hoang | VP, Research and Development | A | +40,000 deriv. | — |
| 2022-02-22 | Juan Vera | Chief Scientific Officer & COO | A | +160,000 deriv. | — |
| 2022-02-22 | Nadia Agopyan | VP, Regulatory Affairs | A | +40,000 deriv. | — |
| 2022-02-22 | Mythili Koneru | Chief Medical Officer | A | +160,000 deriv. | — |
| 2021-12-09 | Katharine Knobil | Director | A | +125,000 deriv. | — |
| 2021-06-10 | Frederick Gerald Wasserman | Director | A | +12,658 | — |
| 2021-06-10 | Norman David Eansor | Director | A | +12,658 | — |
| 2021-06-10 | John Robert Wilson | Director | A | +12,658 | — |
| 2021-06-10 | Steve Elms | Director | A | +12,658 | — |
| 2021-06-10 | David Laskow-Pooley | Director | A | +12,658 | — |
| 2021-05-20 | Frederick Gerald Wasserman | Director | Buy | +10,000 | +$24.10K |
| 2021-03-18 | Scott D Sandell | 10%+ Owner | Buy | +5,714,285 | +$10.00M |
| 2021-03-18 | Peter W. Sonsini | 10%+ Owner | Buy | +5,714,285 | +$10.00M |
| 2021-03-18 | Forest Baskett | 10%+ Owner | Buy | +5,714,285 | +$10.00M |
| 2021-03-18 | Mohamad Makhzoumi | 10%+ Owner | Buy | +5,714,285 | +$10.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| NEA Partners 16, L.P. | 10%+ Owner | 1,625,678 | $1.47M |
| Steve Elms | Director | 328,338 | $297.61K |
| Juan Vera | Chief Executive Officer | 267,184 | $242.18K |
| Norman David Eansor | Director | 23,855 | $21.62K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRKR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.